POTOMAC, MARYLAND — August 19, 2025 — Leads & Copy — IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, has announced its financial results for the quarter ended June 30, 2025.
The company cited accelerated progress on its Phase 2 CALMA trial in Alzheimer’s disease, progress in the development of MINT-AD, and extension of its undrawn $12M credit facility as highlights of the quarter.
CEO of IGC Pharma, Ram Mukunda, stated that the company began fiscal 2026 with solid strategic momentum, advancing multiple programs that position IGC for meaningful value creation this fiscal year.
Strategic and operational highlights for the quarter include the expansion of trial sites across North America to support enrollment in the CALMA Phase 2 trial of IGC-AD1 and the presentation of genetic toxicology safety data for IGC‑AD1’s active pharmaceutical ingredients at the 2025 Genetic Toxicology Association Meeting on May 8, 2025.
On June 24, 2025, the Company and O-Bank agreed to extend the $12 million credit facility.
IGC is cutting costs and shifting resources to complete the CALMA Phase 2 trail and implement MINT-AD and raised approximately $3.5 million via private placements and at-the-market (ATM) offering.
IGC’s Principal Scientist Dr. Jagadeesh Rao received a Best Researcher Award at the 11th Annual World Neuroscience Awards on July 21, 2025.
The company presented posters at the Alzheimer’s Association International Conference (AAIC) in Toronto between July 29 and 30, 2025, which included new data on MINT-AD.
The Company generated approximately $328 thousand in revenue, representing an increase of 21% compared to approximately $272 thousand generated during the three months ended June 30, 2024. SG&A expenses decreased by approximately $462 thousand or 28% to approximately $1.2 million. Research and Development expenses decreased by approximately $38 thousand or 4% to approximately $851 thousand. The net loss for the three months ended June 30, 2025, was approximately $1.6 million or $0.02 per share, compared to approximately $2.3 million or $0.03 per share for the three months ended June 30, 2024.
As of June 30, 2025, the Company has not drawn on the $12 million available under the Credit Agreement with O-Bank.
Contact:
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
Source: IGC Pharma
